Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab with SOX for Gastric Cancer with Liver Metastases
NCT05325528Phase 3Recruiting
- Sponsor
- Zhejiang University
- Start
- Apr 2022
- Primary completion
- Aug 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of tislelizumab in gastric cancer (GC), sponsored by Zhejiang University. Started Apr 2022; status: recruiting.
02
Drugs
tislelizumab
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT05325528.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05325528.